Literature DB >> 27909890

Does severity of cerebral MRI lesions in congenital CMV infection correlates with the outcome of cochlear implantation?

Stefan Lyutenski1, Friedrich Götz2, Alexandros Giourgas1, Omid Majdani1, Eva Bültmann2, Heinrich Lanfermann2, Thomas Lenarz1, Anja M Giesemann3.   

Abstract

The objective is to investigate whether there is a correlation between the severity of typical brain lesions in congenital cytomegalovirus (cCMV) infection and cochlear implant (CI) outcome. The design of the study is a retrospective single-institutional chart review (2005-2015), performed in a tertiary academic referral center. 23 children with typical signs of cCMV infection on cerebral magnetic resonance imaging (MRI) and bilateral severe-to-profound sensorineural hearing loss were retrospectively evaluated. They were graded in three groups according to the severity of brain involvement. The average implantation age of the first CI is 1.8 years (range 0.6-5.8). Five patients were implanted unilaterally, 18 bilaterally. The average follow-up time after implantation was 3.3 years (range 0.6-6.9). Hearing performance was assessed using the Categories of Auditory Performance (CAP), and speech development was assessed using Speech Intelligibility Rating (SIR). The outcome in each group showed great variation. The majority of children achieved moderate-to-good auditory and speech rehabilitation. The children with severe MRI changes had comparatively better auditory than speech scores. There were children with good auditory performance (CAP ≥6) both in grades II and III, while poor performers (CAP ≤3) were encountered in each group. The severity of brain lesions on its own does not directly correlate with the outcome of cochlear implantation. Despite good retrospective diagnostic evidence of cCMV infection through MRI patterns, this has no predictive role for future hearing and speech rehabilitation.

Entities:  

Keywords:  Cochlear implant; Cytomegalovirus infection; MRI; Polymicrogyria

Mesh:

Year:  2016        PMID: 27909890     DOI: 10.1007/s00405-016-4408-4

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  23 in total

1.  Cochlear implantation in children deafened by cytomegalovirus: speech perception and speech intelligibility outcomes.

Authors:  Jayne M Ramirez Inscoe; Thomas P Nikolopoulos
Journal:  Otol Neurotol       Date:  2004-07       Impact factor: 2.311

2.  Congenital cytomegalovirus infection diagnosed by polymerase chain reaction with the use of preserved umbilical cord in sensorineural hearing loss children.

Authors:  Hiroshi Ogawa; Yoko Baba; Tatsuo Suzutani; Naoki Inoue; Eiko Fukushima; Koichi Omori
Journal:  Laryngoscope       Date:  2006-11       Impact factor: 3.325

Review 3.  Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment.

Authors:  Scott D Grosse; Danielle S Ross; Sheila C Dollard
Journal:  J Clin Virol       Date:  2007-10-24       Impact factor: 3.168

4.  Impact of newborn hearing screening: comparing outcomes in pediatric cochlear implant users.

Authors:  Birgit Philips; Paul Corthals; Leo De Raeve; Wendy D'haenens; Leen Maes; Annelies Bockstael; Hannah Keppler; Freya Swinnen; Eddy De Vel; Bart Vinck; Ingeborg Dhooge
Journal:  Laryngoscope       Date:  2009-05       Impact factor: 3.325

5.  Speech intelligibility in children after cochlear implantation.

Authors:  M C Allen; T P Nikolopoulos; G M O'Donoghue
Journal:  Am J Otol       Date:  1998-11

6.  Cochlear implantation in children with congenital cytomegalovirus infection.

Authors:  Haruo Yoshida; Yukihiko Kanda; Haruo Takahashi; Ikue Miyamoto; Tomomi Yamamoto; Hidetaka Kumagami
Journal:  Otol Neurotol       Date:  2009-09       Impact factor: 2.311

Review 7.  Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention.

Authors:  Maxim C-J Cheeran; James R Lokensgard; Mark R Schleiss
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

8.  Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection.

Authors:  Marjo S van der Knaap; Gerre Vermeulen; Frederik Barkhof; Augustinus A M Hart; J Gerard Loeber; Jan F L Weel
Journal:  Radiology       Date:  2004-02       Impact factor: 11.105

9.  Congenital cytomegalovirus infection of the brain: imaging analysis and embryologic considerations.

Authors:  A J Barkovich; C E Lindan
Journal:  AJNR Am J Neuroradiol       Date:  1994-04       Impact factor: 3.825

10.  RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection.

Authors:  Marco Henneke; Simone Diekmann; Andreas Ohlenbusch; Jens Kaiser; Volkher Engelbrecht; Alfried Kohlschütter; Ralph Krätzner; Marcos Madruga-Garrido; Michèle Mayer; Lennart Opitz; Diana Rodriguez; Franz Rüschendorf; Johannes Schumacher; Holger Thiele; Sven Thoms; Robert Steinfeld; Peter Nürnberg; Jutta Gärtner
Journal:  Nat Genet       Date:  2009-06-14       Impact factor: 38.330

View more
  3 in total

1.  Cytomegalovirus Seropositivity and Suicidal Behavior: A Mini-Review.

Authors:  Marco Paolini; David Lester; Michael Hawkins; Ameth Hawkins-Villarreal; Denise Erbuto; Andrea Fiorillo; Maurizio Pompili
Journal:  Medicina (Kaunas)       Date:  2019-12-12       Impact factor: 2.430

2.  Prediction of the Outcome of Cochlear Implantation in the Patients with Congenital Cytomegalovirus Infection based on Magnetic Resonance Imaging Characteristics.

Authors:  Jae Joon Han; Yun Jung Bae; Seul Ki Song; Jae-Jin Song; Ja-Won Koo; Jun Ho Lee; Seung Ha Oh; Bong Jik Kim; Byung Yoon Choi
Journal:  J Clin Med       Date:  2019-01-24       Impact factor: 4.241

3.  The Correlation of Congenital CMV Infection and the Outcome of Cochlear Implantation.

Authors:  Simon-Pierre H Bolduc; Richard Bussières; Daniel Philippon; Mathieu Côté
Journal:  J Int Adv Otol       Date:  2021-05       Impact factor: 1.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.